|Home | About | Journals | Submit | Contact Us | Français|
Mutations in both RAS and the PTEN/PIK3CA/AKT signaling module are found in the same human tumors. PIK3CA and AKT are downstream effectors of RAS, and the selective advantage conferred by mutation of two genes in the same pathway is unclear. Based on a comparative molecular analysis, we show that activated PIK3CA/AKT is a weaker inducer of senescence than is activated RAS. Moreover, concurrent activation of RAS and PIK3CA/AKT impairs RAS-induced senescence. In vivo, bypass of RAS-induced senescence by activated PIK3CA/AKT correlates with accelerated tumorigenesis. Thus, not all oncogenes are equally potent inducers of senescence and, paradoxically, a weak inducer of senescence (PIK3CA/AKT) can be dominant over a strong inducer of senescence (RAS). For tumor growth, one selective advantage of concurrent mutation of RAS and PTEN/PIK3CA/AKT is suppression of RAS-induced senescence. Evidence is presented that this new understanding can be exploited in rational development and targeted application of pro-senescence cancer therapies.
Different human cancers frequently arise due to genetic and epigenetic alterations in the same relatively small number of cancer pathways. Commonly mutated pathways include the Receptor Tyrosine Kinase (RTK)-RAS-BRAF growth factor signaling pathway, and the ARF-MDM2-p53 and p16-cyclin D1-pRB tumor suppressor pathways (Yeang et al., 2008). Although these same pathways are commonly deregulated in different tumor types, the specific gene that is altered often varies between tumors. For example, approximately 70% of melanomas harbor mutations in BRAF, with most of the remainder containing mutations in N-RAS (Brose et al., 2002; Davies et al., 2002; Pollock and Meltzer, 2002). In most cases, mutations in N-RAS and BRAF are mutually exclusive, presumably because there is no selective advantage for a tumor cell to alter both genes, since they act in the same linear signaling pathway.
However, the genetics of human cancers is not always this simple. An important effector of RAS is the lipid kinase, PIK3CA, and its downstream effector, protein kinase AKT (hereafter referred to as the PIK3CA/AKT signaling module) (Shaw and Cantley, 2006). PIK3CA/AKT is also negatively regulated by the lipid phosphatase PTEN, which is itself frequently mutated in human cancers. Surprisingly, mutations in both RAS and the PTEN/PIK3CA/AKT signaling axis can be found in the same tumors. For example, Vogelstein and coworkers recently reported that approximately 24% of human colon cancers harbor mutations in both K-RAS and PIK3CA (Parsons et al., 2005). Mutations in RAS genes and PIK3CA also co-occur in endometrial and thyroid cancer and Acute Lymphoblastic Leukemia (ALL) (Yeang et al., 2008). Some pancreatic cancers contain K-RAS mutations and amplification of AKT2 (Tuveson and Hingorani, 2005). Since PIK3CA/AKT is an effector of RAS, the specific selective advantage conferred by simultaneous mutation of two genes in the same pathway is unclear. In this manuscript, we set out to understand the molecular basis of the selective advantage conferred by concurrent mutation of RAS and PIK3CA/AKT in human tumors.
Oncogene-induced cellular senescence (OIS) is a permanent cell growth arrest caused by an activated oncogene within a primary untransformed cell (Adams, 2009). Although oncogenes are best known for their ability to drive transformation, a single oncogene in a primary cell often activates senescence as a tumor suppression mechanism. Activation of senescence depends on the pRB and p53 tumor suppressor pathways. Many studies have demonstrated the role of OIS as an in vivo tumor suppression mechanism. For example, many benign neoplasms harboring activated oncogenes contain senescent cells (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Courtois-Cox et al., 2006; Michaloglou et al., 2005). In a number of mouse models, inactivation of the senescence program allows progression of such benign precursor lesions to full-blown malignant cancers (Braig et al., 2005; Chen et al., 2005; Dankort et al., 2007; Ha et al., 2007; Sarkisian et al., 2007; Sun et al., 2007). Underscoring the ability of senescence to block tumor growth, its reactivation in murine tumors is associated with tumor regression (Ventura et al., 2007; Xue et al., 2007).
In addition to proliferation arrest, cell senescence is associated with many other phenotypes, and depends on activation of various signaling and effector pathways. In the nucleus of senescent cells, activated DNA damage signaling pathways, reflected in a focal distribution of DNA damage sensing proteins, γH2AX and 53BP1, are instrumental in driving senescence (d’Adda di Fagagna, 2008). Also, formation of specialized domains of facultative heterochromatin, called Senescence Associated Heterochromatin Foci (SAHF), is thought to silence proliferation promoting genes such as cyclin A2, thereby contributing to a more permanent cell cycle arrest (Narita et al., 2003). Formation of SAHF depends on a complex of histone chaperones, HIRA/UBN1/ASF1a (Banumathy et al., 2009; Zhang et al., 2005). In turn, function of this chaperone complex in senescent cells depends on phosphorylation of HIRA by GSK3β and recruitment of HIRA to a subnuclear organelle, the PML body (Ye et al., 2007). Notably, GSK3β has also been shown to be an important inducer of senescence in other contexts (Kortlever et al., 2006; Liu et al., 2008; Zmijewski and Jope, 2004).
Senescent cells also upregulate autophagy (Gamerdinger et al., 2009; Young et al., 2009), an organelle recycling process, and this might contribute to remodeling of senescent cells and provide the raw materials for altered biosynthetic processes. Prominently, senescent cells show a marked change in their secretory program (Coppe et al., 2008). Upregulated genes whose products are secreted from senescent cells include cytokines and chemokines, such as IL6 and IL8, as well as extracellular proteases, such as Matrix MetalloProteinases (MMPs) (Acosta et al., 2008; Kuilman et al., 2008; Xue et al., 2007). Secretion of these extracellular signaling molecules, collectively referred to as the senescence secretome, may facilitate clearance of senescent cells by the immune system, and so limit tumor growth.
Given the apparent potency of OIS in tumor suppression, it is not surprising that many oncogenes have been reported to induce OIS. However, previous studies do not present a clear picture regarding the ability of activated PIK3CA/AKT to induce senescence (see Discussion). In this study, by profiling the full spectrum of phenotypes that constitute the senescent state, we show that activation of the PIK3CA/AKT pathway is a poor inducer of senescence, compared to activated RAS. This manifests as an inefficient proliferation arrest, a deficient senescence secretome, weak DNA damage signaling and autophagy and no detectable SAHF. Remarkably, we find that, when both pathways are activated, the senescence-impaired PIK3CA/AKT phenotype is in some respects dominant over RAS-induced senescence. The dominance of PIK3CA/AKT depends on the ability of this pathway to intersect and counteract downstream effectors of RAS-induced senescence, such as GSK3β and likely mTOR. The significance of GSK3β in human cancer is underscored by the demonstration that a high level of phosphorylated GSK3β is a predictor of poor survival in human pancreatic cancer. In a mouse model of pancreatic carcinogenesis, genetic inactivation of PTEN, an inhibitor of PIK3CA/AKT, leads to bypass of RAS-induced proliferation arrest (with features of senescence) and accelerated formation of pancreatic ductal adenocarcinoma (PDAC). Together, these results indicate that activation of the PIK3CA/AKT pathway cooperates with activation of RAS in tumorigenesis through its ability to suppress RAS-induced senescence.
We set out to compare the spectrum of senescence phenotypes induced by activated RAS and PIK3CA/AKT. Human BJ fibroblasts immortalized with hTERT (BJ-hTERT) were infected with a control retrovirus or viruses encoding activated H-RAS (RASG12V) or activated myristoylated AKT1 (mAKT1), or an shRNA (shPTEN) to knock down the PIK3CA pathway inhibitor, PTEN. As expected, cells infected with activated RAS assumed a flattened vacuolated morphology, characteristic of senescence induced by this oncogene (Figure 1a). Compared to RASG12V-infected cells, mAKT1 and shPTEN-transduced fibroblasts were less vacuolated, but did become larger and flatter. However, activated AKT1 and shPTEN were both weaker inducers of proliferation arrest (Figure 1b and Supplementary Figure 1a). Consistent with this, cells expressing mAKT1 expressed reduced amounts of cyclin A, and exhibited some biochemical changes consistent with senescence, such as dephosphorylation of pRB and upregulation of p53 and p21CIP1 (Figure 1c and Supplementary Figure 1b). But, mAKT1 tended to be less efficient in these respects than RASG12V (Figure 1c and Supplementary Figure 1b), and after passaging at least a proportion of mAKT1-expressing cells did resume growth (data not shown). Similarly, shPTEN failed to arrest colony outgrowth after infection and drug selection (Supplementary Figure 1c). In line with these observations, only activated RAS upregulated expression of p16INK4a, an activator of the p16-cyclin D1-pRB tumor suppressor pathway and key effector of senescence-associated proliferation arrest (Supplementary Figure 1d). Our results suggest that perturbation of this pathway can induce some features of senescence, but is markedly less potent in this regard than is activated RAS.
In light of these provocative differences between activated RAS and PIK3CA/AKT, we investigated the status of other molecular markers of senescence in mAKT1 and RASG12V-transduced cells. Induction of senescence by activated RAS has been shown previously to depend on RAS-induced hyper-replication or unscheduled DNA synthesis, and subsequent DNA damage (d’Adda di Fagagna, 2008). We monitored oncogene-induced DNA damage in mAKT1 and RASG12V-transduced cells by examining two commonly used markers of DNA damage, γH2AX and 53BP1. Cells transduced with RASG12V, as expected, had an increase in DNA damage over control cells. However, transduction of activated AKT1 did not lead to an increase in DNA damage, as judged by either γH2AX or 53BP1 (Figure 1d, e and Supplementary Figure 1e, f). When we examined levels of γH2AX by western blotting, we observed consistent results (Supplementary Figure 1g). Thus, analysis of DNA damage signals support the notion that activated AKT1, compared to RASG12V, does not induce the full senescence program.
In RASG12V-infected cells, induction of autophagy is also important for onset of senescence (Gamerdinger et al., 2009; Young et al., 2009). To compare autophagy in RASG12V and mAKT1- infected cells, we introduced either oncogene together with GFP-LC3, a fluorescent fusion protein that is incorporated into autophagosomes (Klionsky et al., 2008). As shown previously, activated RAS induced formation of autophagosomes, reflected in a punctate distribution of GFP-LC3 in the cytoplasm (Figure 1f). However, by this measure, activated AKT1 failed to induce autophagy. These results also support the notion that, compared to activated RAS, activated AKT1 does not induce a robust senescence program.
Next, we compared the ability of activated RAS, AKT and shPTEN to induce senescence-associated chromatin changes, manifest as SAHF and recruitment of the HIRA histone chaperone to PML bodies (Narita et al., 2003; Zhang et al., 2005). SAHF can be visualized by conventional epifluorescence microscopy as punctate domains of DAPI-stained chromatin that stain with specific heterochromatin proteins, such as histone variant macroH2A. We observed characteristic macroH2A-containing SAHF in cells transduced with activated RAS (and an activated mutant of one of its effectors, BRAF (BRAFV600E)), but not in activated AKT1- or shPTEN-transduced cells (Figure 2a-b and Supplementary Figure 2). Consistent with this, activated RAS and BRAF also triggered HIRA’s relocalization to PML bodies, whereas activated AKT1 did not (Figure 2a, c). Rather, activated AKT1-infected cells were much like control, lacking both HIRA foci and SAHF. Finally, we compared induction of the senescence secretome by activated RAS and AKT1, by quantitative PCR. Activated RAS robustly increased expression of IL6, IL8, MMP1 and MMP8, as expected. However, activated AKT1 was unable to achieve this (Figure 2d). To confirm and extend these findings, we performed a gene expression microarray of cells infected with activated RAS, activated AKT1 or control. Gene Ontology (GO) classification of genes induced by RASG12V compared to control showed that the top-ranked GO term was “Inflammation”. Specific genes in this group upregulated by RASG12V included IL8, CXCL2 and IL1α. This GO group as a whole was not significantly altered by mAKT1, and, typically, individual genes in this group were not upregulated by this oncogene (Figure 2e). In sum, by several measures, namely proliferation arrest, DNA damage signaling, autophagy, activation of HIRA and formation of SAHF and upregulation of the secretome, activated AKT1 fails to induce a senescence program as robust as that induced by activated RAS.
Knowing that some human tumors contain mutations in both RAS and the PTEN/PIK3CA/AKT axis (Parsons et al., 2005; Tuveson and Hingorani, 2005; Yeang et al., 2008), we wanted to know whether the senescence program of cells containing activated RAS and AKT was more or less robust than cells containing activated RAS alone. To do this, we transduced IMR90 fibroblasts with each oncogene alone, or both activated AKT and RAS together, and scored markers of senescence. First, we asked whether activated AKT1 is able to suppress RASG12V-induced upregulation of p16INK4a. As shown previously (Supplementary Figure 1d), activated RAS caused upregulation of p16INK4a, whereas activated mAKT1 did not. Coinfection of RASG12V and mAKT1 showed that activated AKT1 suppressed RASG12V-induced upregulation of p16INK4a (Supplementary Figure 3a). Next, we looked at recruitment of HIRA to PML bodies and formation of SAHF. Compared to RASG12V alone, co-expression of activated AKT and RAS decreased both SAHF formation and HIRA foci (Figure 3a-d). Activated RAS and AKT were both efficiently expressed in all infections (Figure 3b). Significantly, we also observed that activated BRAF is a more potent inducer of SAHF than is activated RAS (Figure 3e). This is consistent with the ability of RAS, but not BRAF, to activate AKT1 (Supplementary Figure 3b) (Shaw and Cantley, 2006), which in turn is able to antagonize SAHF formation. Finally, we examined indicators of autophagy in single or double oncogene-infected cells. Consistent with activated RAS-induced upregulation of autophagy described previously and demonstrated in Figure 1f, activated RAS caused accumulation of LC3-II, the lipidated form of the protein that is incorporated into autophagosomes and which characteristically migrates faster in SDS-PAGE (Klionsky et al., 2008) (Figure 3f). In contrast, cells transduced with both RASG12V and mAKT1 showed decreased LC3-II and an increased level of p62, a protein whose accumulation is indicative of decreased autophagy (Klionsky et al., 2008). These experiments indicate that the combination of activated AKT and RAS in cells results in a less complete senescence program than does activated RAS alone.
We next wanted to know the mechanism by which activated AKT1 antagonizes aspects of RASG12V-induced senescence. Since AKT1 activates mTOR and mTOR is a potent inhibitor of autophagy (He and Klionsky, 2009), we hypothesized that activated AKT1 suppresses RASG12V-induced autophagy by activation of mTOR. Consistent with this idea, in the presence of activated RAS, activated AKT1 activated mTOR, as judged by phosphorylation of mTOR substrates, 4EBP1 and p70S6K (Figure 4a). With respect to SAHF, we previously showed that activated RAS induces HIRA localization to PML bodies and formation of SAHF through its ability to activate GSK3β (Ye et al., 2007). In contrast, AKT is known to directly inhibit GSK3β through inhibitory phosphorylation on serine 9 (Cross et al., 1995). Therefore, we hypothesized that mAKT1’s ability to block RASG12V-induced SAHF formation might depend on its ability to phosphorylate and inhibit GSK3β. Consistent with this idea, in cells coexpressing activated RAS and AKT, GSK3β was heavily phosphorylated on serine 9 (GSK3βpS9) (Figure 4b). This indicates that RASG12V-induced activation of GSK3β is over-ridden by mAKT1-induced inhibition of GSK3β. To test our hypothesis further, we expressed activated AKT1 with or without a non-phosphorylatable mutant of GSK3β (GSK3βS9A), and found that, even in the presence of activated AKT1, GSK3βS9A was able to induce both localization of HIRA to PML bodies and SAHF formation (Figure 4c-e). We verified appropriate expression of GSK3βS9A and activated AKT by western blotting (Figure 4d). These results are consistent with the notion that activated AKT1 suppresses HIRA activation and formation of SAHF, at least in part, through phosphorylation and inhibition of GSK3β. Underscoring the importance of AKT1-mediated GSK3β phosphorylation in human cancer, we found that in a pancreatic cancer Tissue MicroArray (TMA) the level of GSK3βpS9 correlated with poor patient survival, independent of tumor size, tumor grade, perineural invasion, resection margin involvement and lymph node status (Figure 5a, b). Phosphorylation and activation of AKT1 and its downstream effector, mTOR, and combined phosphorylation and activation of AKT1 and mTOR similarly correlated with poor disease outcome (Figure 5c, d and Supplementary Figure 4 Supplementary Tables 1-5), also emphasizing the significance of activated AKT1 in this disease.
We next wanted to test whether activation of PIK3CA/AKT signaling is able to suppress activated RAS-induced senescence and accelerate tumor formation in vivo. To do this, we utilized a mouse model in which expression of activated RAS is restricted to the cells of the pancreas, by virtue of a conditional RAS allele (K-RASG12D) at its normal genomic locus that can be activated by Cre-mediated recombination, and pancreas specific expression of Cre recombinase under control of a PDX1 promoter (Hingorani et al., 2003). These PDX1-Cre/RASG12D animals develop normally, but develop benign precursor lesions termed pancreatic intraepithelial neoplasms (PanINs) that can, with long latency, progress to form PDAC. As shown previously (Morton et al., 2010b), these neoplastic lesions stain positively for markers of senescence, including SA β-gal and expression of p53 and p21CIP1 (Figure 6a, b). Conversely, they largely lack markers of proliferation, namely Ki67, MCM2 expression and incorporation of BrdU (Figure 6a-b). To test the impact of PIK3CA/AKT pathway activation on this activated RAS-induced in vivo senescence-like state, the PDX1-Cre/RASG12D animals were crossed to animals that have one or both PTEN alleles flanked by Cre recombination sites (Suzuki et al., 2001), to drive simultaneous activation of RAS and partial or biallelic inactivation of PTEN in the pancreas (PDX1-CRE/RASG12D/PTEN). Significantly, complete inactivation of PTEN in the mouse pancreas does not induce senescence (Stanger et al., 2005)(Supplementary Figure 5a). Comparing PanINs in the pancreata of 6 week old PDX1-Cre/RASG12D and PDX1-Cre/RASG12D/PTEN animals, we found that inactivation of PTEN largely abolished expression of senescence markers, p53, p21 and SA β-gal (Figure 6a-b). Consistent with the idea that inactivation of PTEN facilitates a complete bypass the senescence-like state, we found the PanINs of the PDX1-Cre/RASG12D/PTEN animals to be highly proliferative, as measured by an increase in immunohistochemical staining of Ki67, MCM2 and incoporation of BrdU (Figure 6a, b). Senescence bypass was associated with phosphorylation of GSK3 on serine 9, similar to the in vitro model (Figure (Figure4b4b and and6a).6a). In line with this senescence-like state being a potent tumor suppression mechanism in this in vivo model, expression of activated RAS and concurrent inactivation of PTEN resulted in rapid progression of PanINs into PDAC (Figure 6c and Supplementary Figure 5b), as reported recently (Hill et al., 2010). Previously, we have reported that inactivation of p21CIP1 accelerates tumorigenesis in this model, likely though inactivation of senescence (Morton et al., 2010a). Significantly, deficiency of p21CIP1 did not further accelerate tumorigenesis in PDX1-Cre/RASG12D/ PTENfl/+ animals (Figure 6d), indicating that loss of p21CIP1 and PTEN accelerate PDAC via the same pathway, further implicating loss of PTEN in abrogation of senescence in this model.
IHC analysis of PTEN indicated that tumors arising from PDX1-Cre/RASG12D/PTENfl/+ mice had lost the second allele of PTEN (Supplementary Figure 5c). Also, the effects of PTEN disruption were more marked when both, rather than one, alleles of PTEN were engineered for inactivation in the pancreas (Figure 6c and Supplementary Figure 5b). Loss of two alleles of PTEN led to an incredibly lethal acceleration of tumorigenesis, leading invariably to rapid death and a mean survival of 15 days (Figure 6c and Supplementary Figure 5b). In these mice, almost the entire pancreas was replaced by neoplastic tissue, with very little normal tissue remaining. Neoplastic tissue contained widespread mitoses, including some aberrant figures (Supplementary Figure 5d). In areas, there was loss of the normal pancreatic architecture with angulated glands, indicating invasive carcinoma (Supplementary Figure 5d). Tumors in these mice were large and exhibited a high proliferative index, as judged by Ki67 and BrdU incorporation (Supplementary Figure 5e-f). These observations suggest that the tumor suppressor function of PTEN in this model conforms to the Knudson “two-hit” paradigm for tumor suppressors.
As expected, tumors that resulted from inactivation of PTEN exhibited a strongly activated AKT signaling pathway, as shown by immunohistochemical staining for activated phosphoserine 473 AKT (Figure 7a and data shown). Consistent with inactivation of PTEN and activation of AKT driving tumorigenesis through inactivation of GSK3β and activation of mTOR, tumors from PDX1-Cre/RASG12D/PTEN mice stained strongly for phosphoserine 9 GSK3β and phospho-mTOR (Figure 7a). Moreover, treatment of PDX1-Cre/RASG12D/ PTENfl/+ mice with rapamycin, a potent inhibitor of mTOR, restored cell senescence, as measured by proliferation arrest (BrdU) and p53 and p21 expression (Figure 7b and Supplementary Figure 6). Taken together, these in vivo data support our hypothesis that inactivation of PTEN and activation of AKT and its downstream effector, mTOR, is capable of antagonizing activated RAS-induced proliferation arrest (with features of senescence) leading to rapid acceleration of tumorigenesis.
Previous studies do not present a clear picture regarding the ability of activated PIK3CA/AKT to induce senescence. Some reports have indicated that activation of the PIK3CA/AKT pathway does induce senescence (Chen et al., 2005; Majumder et al., 2008; Miyauchi et al., 2004; Nogueira et al., 2008; Oyama et al., 2007). Other reports have concluded that PIK3CA/AKT activity is a weak inducer of senescence (Lin et al., 1998), is downregulated in senescence (Courtois-Cox et al., 2006; Young et al., 2009), and can antagonize senescence (Courtois-Cox et al., 2006; Kortlever et al., 2006; Tresini et al., 1998). A recent report on PTEN loss-induced senescence (PICS) supports our finding that senescence induced by PIK3CA/AKT activation is not associated with activation of DNA damage signaling, but did not examine chromatin changes, autophagy and the senescence secretome (Alimonti et al., 2010). In this study, by directly comparing activated RAS and PIK3CA/AKT, we find that the latter is not an efficient inducer of senescence. Specifically, we show that inactivation of PTEN and activation of AKT is impaired in its ability to induce senescence, as recorded by multiple effectors of senescence, including upregulation of p16, induction of DNA damage, recruitment of HIRA to PML bodies, formation of SAHF and upregulation of autophagy. Importantly, we also show that activation of PIK3CA/AKT is deficient in its ability to drive two functional outputs of the senescence program that are central to senescence-mediated tumor suppression, namely upregulation of the senescence secretome and efficient proliferation arrest. Most important, concurrent activation of both RAS and PIK3CA/AKT impairs RAS-induced senescence, both in vitro and in vivo.
Activated PIK3CA/AKT suppresses senescence induced by activated RAS through multiple routes. First, activated AKT1 reversed the upregulation of p16INK4a induced by activated RAS. Second, GSK3β kinase is another key nodal point at which signals from activated RAS and PIK3CA/AKT interact. We and others have previously shown that activation of GSK3β kinase contributes to onset of senescence (Kortlever et al., 2006; Liu et al., 2008; Ye et al., 2007; Zmijewski and Jope, 2004). Specifically, we showed that activation of GSK3β phosphorylates the HIRA histone chaperone, thereby localizing this protein to PML bodies and instigating the formation of SAHF (Ye et al., 2007). Here we present evidence that activated PIK3CA/AKT suppresses RASG12V-induced HIRA relocalization and formation of SAHF through its ability to phosphorylate and inhibit GS3Kβ. The significance of the PIK3CA/AKT-GSK3β signaling axis in human cancer is underscored by our finding that a high level of AKTpS473 (with or without high mTORpS2448) or GSK3βpS9 is a predictor of poor survival in human pancreatic cancer, independent of other common prognostic indicators. Third, activated PIK3CA/AKT and activated RAS antagonize each other through mTOR signaling. mTOR is well-documented to be a potent repressor of autophagy (He and Klionsky, 2009). While activated RAS inhibits mTOR activity to upregulate autophagy and promote senescence (Young et al., 2009)(Figure), activated AKT1 was able to activate mTOR even in the presence of activated RAS, likely explaining the ability of mAKT1 to inhibit RASG12V-induced autophagy. To affirm this in vivo, in mice haboring activated RAS and activated PIK3CA/AKT signaling, the potent mTOR inhibitor, rapamycin, reactivated RAS-senescence. We conclude that activated PIK3CA/AKT suppresses RAS-induced senescence through its ability to intersect with and antagonize several outputs of chronic activated RAS, including upregulation of p16INK4a, activation of GSK3β and repression of mTOR. While activated PIK3CA/AKT signaling is known to have many targets in the cell, TMA analysis of human pancreatic cancer underscored GSK3β and mTOR as important targets in this disease. Phosphorylation of all three proteins was significantly directly correlated (Supplementary data), and high phosphorylation of each protein is a predictor of poor patient survival. Thus, the PIK3CA/AKTGSK3β/mTOR axis is an important driver of disease outcome in human pancreatic cancer.
Although activation of AKT1 impaired RASG12V-induced senescence in vitro by at least three criteria (suppression of p16INK4a, SAHF and autophagy), it did not completely abolish activated RAS-induced senescence, as measured by proliferation arrest (Supplementary Figure 3c). On the other hand, inactivation of PTEN did bypass activated RAS-induced senescence-like arrest in vivo (as measured by proliferation markers) and caused a dramatic acceleration of tumorigenesis. There are several possible explanations of this difference between the in vitro and in vivo models, including differences between cell types, use of RASG12V in vitro and RASG12D in vivo and influence of cellular microenvironment in vivo. It is also important to note that in the mouse model, we cannot conclude that inactivation of PTEN is sufficient to abrogate senescence in all of the RASG12D-expressing cells. Rather, inactivation of PTEN might weaken the senescence program enough to facilitate complete escape from senescence, but only in cooperation with additional acquired and selected mutations. Regardless, of the correct explanation, the in vitro and in vivo results are consistent in showing that inactivated PTEN/activated AKT can antagonize activated RAS-induced senescence and in vivo this facilitates tumorigenesis.
Our results show that all oncogenes are not equal in their abilities to induce senescence, and, surprisingly, a weak inducer of senescence can be dominant over a strong. This idea has important implications for understanding mechanisms of oncogene cooperation. Concurrent mutations of RAS and the PTEN/PIK3CA/AKT pathway have been described in a number of human tumor types, including colon, endometrium and ALL (Parsons et al., 2005; Yeang et al., 2008). Concurrent mutations are also probable in pancreatic cancer, as RAS mutations are thought to occur in >90% of cases (Tuveson and Hingorani, 2005) and functional inactivation of PTEN by promoter methylation (Asano et al., 2004), decreased mRNA levels (Ebert et al., 2002), loss of protein expression (Altomare et al., 2002; Asano et al., 2004) or loss of heterozygosity (Okami et al., 1998) has also been reported. Furthermore, amplification or activation of AKT2 kinase, related to AKT1, occurs in up to 60% of pancreatic cancers (Altomare et al., 2002; Ruggeri et al., 1998; Schlieman et al., 2003), and AKT is activated in pancreatic cancer based on IHC staining (Semba et al., 2003). Most strikingly, approximately 75% of human colon cancers that contain PIK3CA mutations also harbor mutations in K-RAS (Parsons et al., 2005). In addition, activating mutations of RAS and in the PTEN/PIK3CA/AKT pathway have been shown to cooperatively drive tumorigenesis in mouse models of glioblastoma, endometrium, thyroid and pancreas (Holland et al., 2000; Kim et al., 2010; Miller et al., 2009) (this study). To date, the molecular basis of cooperation between these mutations in human tumors and mouse models has been poorly understood. Here, we present evidence from both in vitro and in vivo studies to indicate that these mutations cooperate, at least in part, through the ability of PTEN/PIK3CA/AKT mutations to suppress RAS-induced senescence, thereby allowing for these oncogenic pathways to cooperate in tumorigenesis. Importantly, this new mechanistic understanding might be exploited as a pro-senescence cancer therapy. Rapamycin is a potent and specific inhibitor of mTOR, a key effector of activated PIK3CA/AKT signaling and is already used in the clinic. We found that rapamycin can reactivate senescence in mouse tumors haboring mutations in both RAS and PTEN, pointing to possible therapeutic activity against human tumors of this, or equivalent, genotype.
IMR90 and BJ (ATCC) cell lines were cultured according to ATCC guidelines in low oxygen (2%) unless otherwise indicated. Fibroblasts were cultured in Dulbecco’s modified Eagle’s medium supplemented with 20% fetal bovine serum.
Two color indirect immunofluorescence and SAHF assays were performed as described previously (Ye et al., 2007; Zhang et al., 2005). SA β-gal staining was performed as described previously (for in vitro studies) (Dimri et al., 1995).
The Pdx1-Cre, LSL-K-RASG12D and PTENflox mice have been described previously (Hingorani et al., 2003; Suzuki et al., 2001). The p21CIP1−/− mice have been previously described (Deng et al., 1995). Conditional LSL-K-RASG12D/+ mice were from Tyler Jacks via MMHCC.
For additional methods see Supplementary Text and Figures.
We are indebted to Daniel Peeper, Masashi Narita and Chris Sell for communication of results prior to publication; to Michael Bouchard, Jane Clifford, Maureen Murphy and Matt Kennedy for helpful discussions and advice; to Stuart Pepper and the CR-UK Microarray Facility, Paterson Institute for microarray analyses; to Colin Nixon for immunohistochemistry; to Jane Hair for curating the NHSGGC biorepository. The lab of PDA is funded by CR-UK (C10652/A10250). Work in the lab of GHE was funded by NIH R01GM062281. The lab of OJS is funded by CR-UK. Thanks to the Scottish Executive Chief Scientist Office (CSO) for funding for NBJ, including the production of tissue microarrays (CSO ref: 41175). Additional support was from Think Pink Scotland.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.